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Background: This pilot study investigated the association between heat shock protein 70 (HSP70) and anti-HSP70
antibodies as well as their changes and rhythm outcome after atrial fibrillation (AF) catheter ablation.
Methods: We studied 67 patients with AF (59±11 years, 66% male, 66% lone AF) undergoing catheter ablation.
Circulating HSP70 and anti-HSP70 antibody levels were quantified using commercially available assays before and 6
months after catheter ablation. Serial 7-day Holter ECGs were used to detect AF recurrences.
Results: At baseline, HSP70 was detectable in 14 patients (21%), but there was no correlation between clinical or
echocardiographic variables and the presence or the level of HSP70. In contrast, patients with paroxysmal AF (n=39)
showed lower anti-HSP70 antibodies (median [IQR] of 43 [28 – 62] μg/ml) than patients with persistent AF (n=28;
53 [41 – 85] μg/ml, p=0.035). Using multivariable regression analysis, AF type was the only variable associated with
anti-HSP70 antibodies (Beta=0.342, p=0.008). At 6 months, HSP70 was present in 27 patients (41%, p<0.001 vs.
baseline). Similarly, there was an increase of anti-HSP70 antibodies (48 [36 – 72] vs. 57 [43 – 87] μg/ml, p<0.001). AF
recurrence rates were higher in patients with HSP70 increase ≥0.025 ng/ml (32 vs. 11%, p=0.038) or anti-HSP70
increase ≥2.5 μg/ml (26 vs. 4%, p=0.033).
Conclusions: HSP70 and anti-HSP70 antibodies may – at least in part – be associated in the progression of AF and
AF recurrence after catheter ablation.
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Heat shock proteins (HSPs) are characterized as molecu-
lar chaperones and have important functions in the pres-
ervation and protection of cells and organs from stress
and injury. The HSPs are subdivided into multimember
families based on the molecular weights of the proteins
encoded such as the HSP90, HSP70, HSP60 and small
HSP families [1]. They seem to play a dominant role in
mediating cytoprotective effects and limit necrosis of
smooth muscle cells exposed to oxidative stress [2].
HSPs are typically regarded as intracellular, but elevated
levels of circulating HSPs have been found under several* Correspondence: jelena.kornej@gmx.de
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reproduction in any medium, provided the orconditions including congestive heart failure, vascular
disease or after acute myocardial infarction [3-6].
HSPs have also been implicated in the pathogenesis of
atrial fibrillation (AF). In particular, myocardial HSP27
has been suggested to have protective effects against the
progression from paroxysmal to persistent AF [7] or
HSP70 against postoperative AF [8,9]. In contrast, circu-
lating HSPs have different functions and may act as
cytokines [10]. However, there is only few data available
on circulating HSP levels in AF [8,11,12], although they
may also be related with AF development [12]. Of inter-
est, antibodies against various HSPs have also been
associated with postoperative AF [13,14].
Catheter ablation has become the cornerstone of non-
pharmacologic AF treatment, but AF recurrences are
frequently observed and their pathophysiology is poorlyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dominant mechanism [15], the possible contribution of
ablation-induced tissue necrosis with subsequent devel-
opment of inflammation and auto-immune reactions
needs further investigation.
Consequently, this pilot study was performed to elab-
orate the potential role of soluble HSP70 (HSPA1A) [16]
and anti-HSP70 antibodies in the AF development by (1)
comparing plasma levels of patients with paroxysmal
and persistent AF with AF-free controls and (2) by
evaluating their response to catheter ablation that
generates myocardial injury and their possible associ-
ation with rhythm outcome.
Methods
Study population
This study enrolled 67 consecutive patients who under-
went left atrial catheter ablation for drug-refractory par-
oxysmal or persistent AF (Table 1) and 34 controls
matched for age, gender and heart disease. Patients with
hematologic, renal, or hepatic impairment, systemic in-
flammation, neoplastic disorders, acute infection or
thyrotoxicosis were excluded. Paroxysmal and persistent
AF was defined according to current guidelines [17].
Paroxysmal AF was defined as self-terminating within 7
days after onset documented by previous ECG or
Holter-ECG. Persistent AF was defined as an AF episode
either lasting longer than 7 days or requiring drug or
direct current cardioversion for termination.
Controls without AF-related symptoms were recruited
from the outpatient clinic and freedom from AF was
verified by previous ECG reports.
In all patients, transthoracic and transesophageal
echocardiography was performed prior to catheter abla-
tion. Left atrial diameter and left ventricular ejectionTable 1 Baseline clinical, echocardiographic, and
laboratory data of the study population
AF population Controls
n=67 n=34
Age (years) 59 ± 11 59 ± 11
Males (%) 66 66
Paroxysmal AF (%) 58 0
Lone AF (%) 66 -
AF history (months) 72 ± 60 -
LVEF (%) 60 ± 9 62 ± 8
LAD (mm) 43 ± 6 41 ± 5
anti-HSP70 antibodies (μg/ml) 48 [36 – 72] 40 [32 – 70]
HSP70 (ng/ml)* 0 [0 – 0] 0 [0 – 0]
hs-CRP (μg/ml) 2.07 ± 1.10 1.80 ± 0.85
HSP70 and anti-HSP70 antibodies are presented as median [IQR].
* detectable in 21% of AF patients and 19% of controls.
LAD = left atrial diameter, LVEF = left ventricular ejection fraction.fraction were determined using standard measurements
and a left atrial thrombus was excluded. All class I or III
antiarrhythmic medications with the exception of
amiodarone were discontinued at least 5 half-lives before
the procedure. The study was approved by the local eth-
ics committee (Medical Faculty, University Leipzig) and
patients provided written informed consent for partici-
pation.
Catheter ablation
Left atrial catheter ablation was performed using a previ-
ously described approach [18]. In brief, patients were
studied under deep propofol sedation with continuous
invasive monitoring of arterial blood pressure and oxy-
gen saturation. Non-fluoroscopic 3D catheter orienta-
tion, CT image integration, and tagging of the ablation
sites were performed using Ensite NavX, Ensite Velocity
(St. Jude Medical, St. Paul, MN, USA) or CARTO 3
(Biosense Webster, Diamond Bar, CA, USA). Trans-
septal access and catheter navigation were performed
with a steerable sheath (Agilis, St. Jude Medical., St.
Paul, MN, USA). Patients presenting with AF at the be-
ginning of the procedure were electrically cardioverted
and ablation was performed during sinus rhythm (i.e. AF
termination with ablation was not attempted). In all
patients circumferential left atrial ablation lines were
placed around the antrum of the ipsilateral pulmonary
veins (irrigated tip catheter, pre-selected tip temperature
of 48°C, and maximum power of 30 – 50 W). In patients
with persistent AF, additional linear lesions were added
at the left atrial roof, the basal posterior wall and the left
atrial isthmus. Ablation of complex fractionated
electrograms was not performed.
After circumferential line placement, voltage and pace
mapping along the ablation line were used to identify
and close gaps. The isolation of all pulmonary veins with
bidirectional block was verified with a multipolar circu-
lar mapping catheter and was defined as the procedural
endpoint.
Follow-up
After ablation, class I and III antiarrhythmic drugs were
not reinitiated. Oral anticoagulation was prescribed for 6
months, and proton pump inhibitors were added for 4
weeks. All patients were followed in the outpatient clinic
for 6 months after the ablation. During this follow-
up period, 7-day Holter recordings were performed 3
and 6 months after the ablation. Additional ECGs and
Holter recordings were obtained when patients’ symptoms
were suggestive of AF. AF recurrence was defined as a
documented AF episode lasting longer than 30 seconds be-
tween 3 and 6 months after the ablation (thus, including a
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recurring AF underwent direct cardioversion. Additional
drug administration was left to the discretion of the
treating physician.
Blood samples
Blood samples were obtained before and 6 months after
catheter ablation. Platelet-poor plasma fractions were
obtained by centrifugation at 20°C for 10 min at 3500 × g,
and plasma were stored at −80°C for subsequent analysis.
Plasma levels of HSP70, anti-HSP70 antibodies and
high-sensitiveC-reactive protein (hs-CRP) were quanti-
fied using commercially available specific enzyme-linked
immunoabsorbent assays (ELISA) according to the manu-
facturers protocol (Hsp70 High Sensitivity EIA Kit - Enzo
Life Sciences ADI-EKS-715; anti-human Hsp70 (total)
ELISA Kit - Enzo Life Sciences ADI-EKS-750; Human High
Sensitivity C-Reactive Protein, hs-CRP ELISA Kit - Cusabio
CSB-E08617h). Results were compared with standard
curves and the lower detection limits were as follows:
HSP70 0.09 ng/ml; anti-HSP70-autoantibodies 6.79 ng/ml;
hs-CRP 0.08 μg/ml. The interassay and intra-assay
precisions were < 10%.Statistical analysis
Statistical analysis was performed according to the
following analysis plan. (1) HSP70 and anti-HSP70 anti-
bodies were compared between AF patients and AF-free
controls. (2) Possible associations between clinical or echo-
cardiographic characteristics and HSP70 or anti-HSP70
antibodies were analyzed for the entire population and then
for the AF cohort. (3) Changes in HSP70 and anti-HSP70
antibodies following catheter ablation were evaluated
and (4) associations between those changes and clini-
cal, echocardiographic or procedural characteristics were
determined. (5) Patient characteristics including HSP70 and
anti-HSP70 antibody levels and changes were compared
between patients with and without recurring AF.
Continuous variables are reported as mean ± one stan-
dard deviation or median with interquartile ranges (IQR),
and categorical variables are reported as frequencies.
Continuous variables were compared using Mann–
Whitney-U-test (unpaired data), Wilcoxon test (paired
data) or ANOVA with post-hoc analysis and catego-
rical variables were compared using the chi-square test.
Multivariable analysis that included variables with a p-value
<.1 found in univariate analysis was performed to identify
independent predictors of baseline HSP70 and anti-HSP70
antibody levels as well as of AF recurrence.
Bonferroni correction for multiple comparisons was not
used and a p value of < .05 was considered statistically
significant.Results
HSP70 and anti-HSP70 antibodies in AF
At baseline, HSP70 was detectable in 21% of the patients
and in 19% of the controls (p=ns). Patients with AF and
AF-free controls showed similar HSP70, anti-HSP70
antibody and hs-CRP levels (Table 1). There was no cor-
relation between clinical or echocardiographic variables
and the presence or the level of HSP70 in both the
entire and the AF cohort. However, in the AF cohort
patients with paroxysmal AF had lower anti-HSP70
antibodies (median 43, IQR 28 – 62 μg/ml) at base-
line compared to patients with persistent AF (53, 41 –
85 μg/ml, p=0.035). Using uni- and multivariable
regression analysis adjusted for age and gender, AF type
was the only variable associated with anti-HSP70 anti-
bodies (Beta=0.342, p=0.008). There was no correlation
between HSP70, anti-HSP70 antibodies and hs-CRP at
baseline.
Response of HSP70 and anti-HSP70 antibodies to catheter
ablation
Total ablation time was 40 ± 18 min and total energy
was 77.279 ± 34.675 J. At 6 months after catheter abla-
tion, HSP70 was present in 27 patients (41%, p<0.001 vs.
baseline). While both the median and the lower quartile
remained at 0 ng/ml the upper quartile increased from 0
to 0.09 ng/ml (p=0.029). Similarly, there was an increase
of anti-HSP70 antibodies (48 [36 – 72] vs. 57 [43 – 87]
μg/ml, p<0.001) while hs-CRP remained unchanged
(2.07 ± 1.1 vs. 2.15 ± 1.2 μg/ml, p=0.425).
There was no relation between clinical, echocardio-
graphic or procedural variables and anti-HSP70 and
CRP levels after 6 months or their changes. In contrast,
in patients with a HSP70 increase in the upper tertile
(≥0.025 ng/ml), total ablation time was longer (50 ± 24
vs. 36 ± 14 min, p=0.012) and ablation energy was
higher (98.889 ± 42.298 vs. 69.103 ± 27.813 J, p=0.024)
compared to patients in the lower and intermediate
tertile. Also, patients with newly detectable HSP70 at
6 months had a longer total ablation time (62 ± 23 vs.
35 ± 14 min, p<0.001) and a higher total ablation energy
(117.056 ± 40.993 vs. 68.108 ± 27.193 J, p<0.001)
compared to patients who had no HSP70 detectable at
baseline and after 6 months.
There was no correlation between HSP70, anti-HSP70
antibodies and hs-CRP at 6 months.
Response of HSP70 and anti-HSP70 antibodies and
rhythm outcome after catheter ablation
AF recurrence between 3 and 6 months occurred in 18%
of the patients. None of the baseline clinical, echocardio-
graphic or laboratory variables was associated with AF
recurrence, but ablation time and energy were higher in
patients with recurring AF (Table 2). AF recurrence rates
Table 2 Comparison of baseline clinical,
echocardiographic, laboratory and procedural variables







Age (years) 59 ± 11 61 ± 12
Males (%) 63 75
Paroxysmal AF (%) 59 50
Lone AF (%) 69 58
AF history (months) 73 ± 62 68 ± 52
Body mass index (kg/m2) 28 ± 4 29 ± 5




LVEF (%) 60 ± 9 56 ± 11
LAD (mm) 43 ± 6 45 ± 9
Total ablation duration (min) 35+/−12 * 61+/−24 *
Total ablation power (J) 67.470 ± 23.732* 117.497 ±
44.058*
anti-HSP70-antibodies (μg/ml) 49, 35 – 73 47, 37 – 56
HSP70 (ng/ml) 0 [0 – 0] 0 [0 – 0.29]
hs-CRP (μg/ml) 2.08 ± 1.18 2.03 ± 0.61
* p<0.05.
Abbreviations and data presentation as in Table 1.
Kornej et al. Journal of Translational Medicine 2013, 11:49 Page 4 of 6
http://www.translational-medicine.com/content/11/1/49were higher in patients with HSP70 increase ≥0.025 ng/ml
(32% vs. 11%, p=0.038) or anti-HSP70 increase ≥2.5 μg/ml
(26 vs. 4 %, p=0.033). When both variables were entered
in multivariable analysis, HSP70 changes in the upper
tertile were the only independent predictor of AF recur-
rence resulting in an odds ratio of 3.733 (95% CI 1.026 –
13.589, p=0.046). However, when ablation time and energy
were added to the model, total ablation time was the only
independent predictor of AF recurrence (OR 1.088, 95%
CI 1.034 - 1.144, p=0.001).
Discussion
Main findings
To the best of our knowledge, this study is the first to
investigate the potential role of circulating HSP70
and anti-HSP70 antibodies in AF and their response
to catheter ablation. Several findings are of special
importance:
1) HSP70 and anti-HSP70 antibodies were similar between
controls and AF patients, but anti-HSP70 antibody
levels were associated with AF type, i.e. patients with
persistent AF had higher anti-HSP70 antibody titers
than their counterparts with paroxysmal AF;
2) HSP70 and anti-HSP70 antibodies increased after AF
catheter ablation and the HSP70 increase wasassociated with total ablation time and energy, i.e.
patients with newly detectable HSP70 or highest
HSP70 increases had longer ablation times and
higher ablation energies;
3) The increase of HSP70 and anti-HSP70 antibodies
was associated with more frequent AF recurrences
after 6 months in univariate but not in multivariable
analysis that revealed total ablation time as sole
predictor for AF recidivism.
Heat shock proteins and antibodies in the progression
from paroxysmal to persistent AF
The rate of progression from paroxysmal to persistent or
permanent AF varies between 8% [19] and 22% [20] after
1 year but responsible mechanisms remain elusive.
Heart failure, previous stroke or TIA, obstructive lung
disease, hypertension, and age have been identified as
independent clinical predictors of AF progression [21].
It has been postulated that underlying cardiovascular
diseases such as heart failure and hypertension cause
chronic atrial stretch and dilatation, which in turn seem
to be important for atrial structural and electrophysio-
logical remodeling supporting the initiation and main-
tenance of AF [22].
Myocardial HSPs, i.e. HSP27 or HSP70 may have sev-
eral protective effects that prevent AF progression [7] or
development of postoperative AF [8,9]. HSP expression
may effect angiotensin-II-induced fibrosis [23] or atrial
myolysis [7]. In addition, HSPs are crucial for the matur-
ation of hERG encoding the alpha subunit of the cardiac
potassium current IKr [24]. Finally, HSPs mediate protect-
ive responses to oxidative stress, which results from mito-
chondrial metabolism dysfunction and further impairs
both mitochondrial and contractile function [25]. Taken
together, HSPs are involved in a variety of aspects of the
atrial remodeling process including structural and electro-
physiological remodeling as well as oxidative stress.
In our study, there were no differences in circulating
HSP70 and anti-HSP70 antibody levels between AF
patients and AF-free controls. In addition, there was no
difference in soluble HSP70 between paroxysmal and
persistent AF, but anti-HSP70 antibodies could be iden-
tified as predictor for AF type. A previous study revealed
no correlation between atrial and soluble HSP70 [8].
Consequently, circulating HSP70 levels do not reflect
myocardial HSP70 expression or function and it is not
surprising that there were no associations with AF pres-
ence or AF type. However, this study is the first to sug-
gest that an anti-HSP70 antibody-mediated immune
response is a possible contributor to the progression of
the remodeling process. In individuals with high anti-
body levels, autoimmune reactions may occur when
these antibodies encounter cells expressing HSPs on
their surface [26]. In fact, antibodies against HSP60 [14]
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of postoperative AF although their exact mode of action
is not known. In addition, previous studies have found
auto-antibodies against M2-muscarinic acetylcholine
and beta-1 adrenergic receptors to promote AF develop-
ment [27,28].
Heat shock proteins and antibodies in recurring AF after
catheter ablation
Isolation of the pulmonary veins with or without cre-
ation of additional linear lesions is the cornerstone of
today’s AF catheter ablation procedures which has also
been applied in our study. Radiofrequency ablation itself
creates a localized myocardial necrosis as reflected by an
increase in troponin, creatine kinase and activation of
the inflammatory cascade [29]. While so far, no study
has assessed the release of HSPs after radiofrequency
catheter ablation, HSP70 release after myocardial infarc-
tion has been reported. Of interest, there was a correl-
ation between the extent of myocardial infarction
expressed by peak troponin or creatine kinase and
HSP70, the latter being persistent for several weeks after
the injury [3,5]. This observation is in support of our
finding on the relation between HSP70 increase and ab-
lation time and energy, even 6 months after catheter
ablation.
Circulating HSPs act differently than myocardial HSPs
and have a role in the systemic inflammatory response
against myocardial injury induced by myocardial infarc-
tion or – as in our case – by catheter ablation. In fact,
HSP70 functions not only as a molecular chaperone, but
also as an activator of the immune system capable of in-
flammatory cytokine production [10]. HSP70 activates
the Toll like receptor-4 (TLR4) signalling pathway and,
as an endogenous natural adjuvant, dose-dependently
induces the downstream production of inflammatory
cytokines [30]. Inflammation in turn has been linked with
recurring AF after cardioversion [31] and catheter abla-
tion [32]. In other words, HSP70 release supports the in-
flammatory response after catheter ablation, although
this response was not captured with hs-CRP in our study.
In addition, both myocardial HSP70 release and expres-
sion may activate the formation of antibodies which is
concordant with the observed increase in anti-HSP70
antibodies. Of interest, in univariate analysis the upper
tertiles of both HSP70 and anti-HSP70 antibodies were
associated with higher AF recurrence rates. However, in
multivariable analysis, only total ablation time was pre-
dictive of AF recurrence indicating more complex abla-
tion procedures as strongest determinant. This finding
does however not rule out a role of auto-immunology
processes in mediating AF initiation which has been
suggested by previous investigations on postoperative
AF [8,9].Study limitations
This study included a highly-selected patient population,
i.e. patients referred for catheter ablation had drug-
refractory AF in most cases. Consequently, it is not
known whether the proposed AF progression via activa-
tion of anti-HSP70 antibodies is specific for refractory
AF or can be found in the general AF population.
Although different HSPs and anti-HSP antibodies have
been implicated in the AF pathophysiology, this study
was limited to the analysis of circulating HSP70 and anti-
HSP70. In addition, this study included only two meas-
urement points, allowing no conclusion regarding the
time course of marker changes. The source of circulating
HSP70 is unknown but the association with ablation time
and energy makes myocardial release and consecutive ac-
tivation of auto-antibodies the likely mechanism although
disease progression can not be ruled out. Finally, this
analysis was restricted to the additional investigation of
hs-CRP and did not include other markers of cardiac
damage or inflammation.
The associations between anti-HSP70 antibodies and
AF type as well as HSP70 and anti-HSP70 antibody
increases and AF recurrence after ablation may point to
parallel phenomena or imply causality which remains to
be clarified although spontaneous variation can not be
ruled out with certainty since repeat measurements in
the control group were not available. In that respect, our
study should be viewed as hypothesis generating and
more mechanistic work is necessary to explore the
evolving field of autoimmunology in AF. This area of in-
vestigation seems of particular clinical interest for AF
prevention as HSP function may be induced and auto-
immune responses suppressed [33].
Monitoring of AF recurrence was limited to serial 7-
day Holter ECGs which is in line with current guidelines
but this strategy may nevertheless have missed asymp-
tomatic AF recurrences.
Finally, Bonferroni correction for multiple comparisons
was not used with possible confounding effects.
In summary, this pilot study is highly exploratory, and
would be better conceived as an initial report aiming to
demonstrate feasibility and raise further hypotheses.
Conclusions
HSP70 and anti-HSP70 antibodies may – at least in part –
be associated in the progression of AF and AF recurrence
after catheter ablation. Additional studies are warranted to
further explore their role in these settings.
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